IDO-1 is found in various immune cells, including dendritic cells and macrophages, where it suppresses immune function by depleting tryptophan an amino acid vital for T-cell activity and generating immunosuppressive byproducts such as kynurenine
Lancet 396 , 12041222 (2020)
Peroxiredoxin 4 protects against ovarian ageing by ameliorating D-galactose-induced oxidative damage in mice
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Cannarella R, La Vignera S, Condorelli RA, Mongioi LM, Calogero AE